论文部分内容阅读
异丁基哌嗪力复霉素(R76—1)是四川抗菌素工业研究所根据国外资料在甲哌力复霉素(利福平)的基础上新研制的一种力复霉素衍生物。经过抗结核菌作用和药理学方面的研究认为是一种较好的抗结核药物。现在已试用临床。 为了提高异丁基哌嗪力复霉素的疗效和减缓耐药性的产生,我们应用异丁基哌嗪力复霉素配合部份其他抗结核药物进行了实验结核病疗效的观察,并希望找到一个较好的配合药物。
Isobutylpiperazine rifamycins (R76-1) is a newly developed erythromycin derivative based on the overseas data of metronidazole and rifampin (Rifampin) in Sichuan Institute of Antibiotics. After anti-TB effect and pharmacological studies that is a better anti-TB drugs. Now trial clinical. In order to improve the curative effect of isobutyramiperagone and slow down the generation of drug resistance, we observed the curative effect of tuberculosis by using isobutylpiperazine combined with part of other anti-tuberculosis drugs and hoped to find A better combination of drugs.